Clinical trial

Evaluation of the Effect of Green Synthesized Nano-silver Fluoride and Silver Diamine Fluoride on Carious Lesions in Children

Name
P-841/08.04.2024
Description
The aim of the present work is to study the effect of the application of Silver diamine fluoride (SDF) and a novel green synthesized Nano-silver fluoride (NSF) on early enamel lesions in primary teeth. Proving their positive effect would be the basis for the development of innovative dental materials and hygienic agents to combat the carious process, which is a critical prerequisite for improving the quality of dental services and reducing dental anxiety and fear.
Trial arms
Trial start
2024-07-29
Estimated PCD
2025-05-01
Trial end
2025-06-01
Status
Recruiting
Phase
Early phase I
Treatment
NSF
Prior to treatment the working field is isolated with cotton rolls. Gingival barrier is used for soft tissue protection. Application of NSF using a microapplicator on the carious lesion for 1 minute. Excess material and gingival barrier are removed. Participants receive oral hygiene instructions.
Arms:
NSF (Gr-N)
Other names:
green synthesized Nano silver fluoride
SDF+KI
Prior to treatment the working field is isolated with cotton rolls. Gingival barrier is used for soft tissue protection. Application of 38% silver diamine fluoride (Riva star 38%, SDI) using a microapplicator on the carious lesion. Immediately afterwards, potassium iodide is applied as a reducing agent. Excess material and gingival barrier are removed. Participants receive oral hygiene instructions.
Arms:
SDF+KI group (Gr-S)
Other names:
Riva star 38%, SDI
Control group
Subjects will receive oral hygiene instructioins to apply fluoridated toothpaste to a toothbrush and brush teeth thoroughly for at least 2 minutes, then expectorate and rinse.
Arms:
Control group (Gr-C)
Size
30
Primary endpoint
Visual assessment using ICDAS II coding system
12 months (Baseline, 1 month, 3 months, 6 months and 12 months)
Activity of a carious lesion using Nyvad Caries Diagnostic Criteria
12 months (Baseline, 1 month, 3 months, 6 months and 12 months)
Change in lesion fluorescence evaluated using diode laser fluorescence device
12 months (Baseline, 1 month, 3 months, 6 months and 12 months)
Eligibility criteria
Inclusion Criteria: * Age: 3 - 8 years * Signed informed consent from parents to participate in the study. Verbal consent from the child for the upcoming manipulations. * Enrolled patients do not have any common diseases or conditions associated with decreased salivation and are not taking medications that suppress salivary flow. Study participants have no cognitive or behavioral impairment. The absence of disease will be confirmed by a history-taking interview with the parent. * Presence of incipient carious lesions (white spots) reaching the enamel interior, assessed with ICDAS system values 01 (first visible enamel change) and 02 (localized visible enamel change) and laser fluorescence values up to 20. The diagnostic threshold of the included lesions is defined as D1 A (active enamel lesion visible after drying) or D2 A (active enamel lesion visible without drying). Criteria for active lesions: under plaque, loss of gloss, loss of smoothness, diffuse borders of the lesion, opaque appearance, white colour, at pre-selection sites (in the cervical third of the enamel). The lesions are located on tooth surfaces with no preceding obturations. * Study participants had not performed remineralization or topical fluoride therapy on the included lesions within six months prior to study inclusion. * Children with no history of allergy to the medications administered. Exclusion Criteria: * Children who are considered medically compromised or medically complex patients. The presence of a medical condition is confirmed by a history interview with the child's parent or guardian and involves common diseases or conditions associated with decreased salivation and intake of medications that suppress salivary flow, cognitive and behavioral disorders. * Patients who underwent remineralizing or topical fluoride therapy to the included lesions in the last six months prior to study inclusion. * Patients with a history of allergy to the administered medication.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['EARLY_PHASE1'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 30, 'type': 'ESTIMATED'}}
Updated at
2024-07-05

1 organization

2 products

1 indication

Product
NSF
Indication
Dental Caries
Product
SDF+KI